References
2. Stergiou G, Kollias A, Parati G, et al. Office blood pressure measurement: the weak cornerstone of hypertension diagnosis. Hypertension 2018;71:813–815.
3. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a Scientific Statement from the American Heart Association. Hypertension 2019;73:e35–e66.
4. Kallioinen N, Hill A, Horswill MS, et al. Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings: a systematic review. J Hypertens 2017;35:421–441.
5. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial. BMJ 2011;342:372.
6. Beckett L, Godwin M. The BpTRU automatic blood pressure monitor compared to 24 hour ambulatory blood pressure monitoring in the assessment of blood pressure in patients with hypertension. BMC Cardiovasc Disord 2005;5:1–6.
7. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021–3104.
8. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010;55:195–200.
9. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159–2219.
10. Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014;32:1359–1366.
11. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015;162:192–204.
12. Pan American Health Organization. Health in the Americas+, 2017 Edition. Summary: Regional Outlook and Country Profiles. Washington, DC: PAHO; 2017.
13. Bossert TJ, Leisewitz T. Innovation and change in the Chilean health system. N Engl J Med 2016;374:1–5.
16. Patel P, Ordunez P, DiPette D, et al. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the Standardized Hypertension Treatment and Prevention Project. J Clin Hypertens 2016;18:1284–1294.
18. Alves LMM, Nogueira MS, De Godoy S, et al. Prevalência de hipertensão do avental branco na atenção primária de saúde. Arq Bras Cardiol 2007;89:28–35.
19. Niiranen TJ, Jula AM, Kantola IM, et al. Prevalence and determinants of isolated clinic hypertension in the Finnish population: the Finn-HOME study. J Hypertens 2006;24:463–470.
20. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–2116.
21. Myers MG. A short history of automated office blood pressure—15 years to SPRINT. J Clin Hypertens 2016;18:721–724.
22. Kollias A, Stambolliu E, Kyriakoulis KG, et al. Unattended versus attended automated office blood pressure: systematic review and meta-analysis of studies using the same methodology for both methods. J Clin Hypertens 2019;21:148–155.
23. Johnson KC, Whelton PK, Cushman WC, et al. Blood pressure measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension 2018;71:848–857.
24. Fujiwara T, Yano Y, Hoshide S, et al. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese general practice population. JAMA Cardiol 2018;3:583–590.
25. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005;19:801–807.
26. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension. Hypertension 2005;45:203–208.
27. Kario K, Shimada K, Schwartz JE, et al. Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Cardiol 2002;39:52–54.
28. Satoh M, Asayama K, Kikuya M, et al. Long-term stroke risk due to partial white-coat or masked hypertension based on home and ambulatory blood pressure measurements: the Ohasama Study. Hypertension 2016;67:48–55.
29. Pierdomenico SD, Pierdomenico AM, Coccina F, et al. Prognostic value of masked uncontrolled hypertension systematic review and meta-analysis. Hypertension 2018;72:862–869.
30. Cohen JB, Lotito MJ, Trivedi UK, et al. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis. Ann Intern Med 2019;170:853–862.
31. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013;62:168–174.
33. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011;343:1–6.
34. Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;163:778.
35. Mancia G, Sega R, Bravi C, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995;13(12 Pt 1):1377–1390.
36. Noubiap JJ, Nansseu JR, Nkeck JR, et al. Prevalence of white coat and masked hypertension in Africa: a systematic review and meta-analysis. J Clin Hypertens 2018;20:1165–1172.
37. Wang YC, Shimbo D, Muntner P, et al. Prevalence of masked hypertension among US adults with nonelevated clinic blood pressure. Am J Epidemiol 2017;185:194–202.
38. Verberk WJ, Kessels AGH, De Leeuw PW. Prevalence, causes, and consequences of masked hypertension: a meta-analysis. Am J Hypertens 2008;21:969–975.
39. Brguljan-Hitij J, Thijs L, Li Y, et al. Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure. Am J Hypertens 2014;27:956–965.
40. Trudel X, Milot A, Brisson C. Persistence and progression of masked hypertension: a 5-year prospective study. Int J Hypertens 2013;2013:836387.
41. Wei FF, Li Y, Zhang L, et al. Persistence of masked hypertension in Chinese patients. Am J Hypertens 2016;29:326–331.
42. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens 2010;28:2036–2045.
43. Hänninen MRA, Niiranen TJ, Puukka PJ, et al. Target organ damage and masked hypertension in the general population: the Finn-Home study. J Hypertens 2013;31:1136–1143.
44. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005;46:156–161.
45. Kikuya M, Ohkubo T, Asayama K, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension 2005;45:240–245.
46. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007;370:1219–1229.
47. Brotman DJ, Davidson MB, Boumitri M, et al. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens 2008;21:92–97.
48. O’Brien E, Kario K, Staessen JA, et al. Patterns of ambulatory blood pressure: clinical relevance and application. J Clin Hypertens 2018;20:1112–1115.
49. Franklin SS, O’Brien E, Thijs L, et al. Masked hypertension a phenomenon of measurement. Hypertension 2015;65:16–20.
53. Shimbo D, Abdalla M, Falzon L, et al. Role of ambulatory and home blood pressure monitoring in clinical practice: a narrative review. Ann Intern Med 2015;163:691–700.
54. Beyhaghi H, Viera AJ. Comparative cost-effectiveness of clinic, home, or ambulatory blood pressure measurement for hypertension diagnosis in US adults. Hypertension 2019;73:121–131.
56. Carrillo-Larco RM, Bernabe-Ortiz A. Sodium and salt consumption in Latin America and the Caribbean: a systematic-review and meta-analysis of population-based studies and surveys. Nutrients 2020;12:556.
57. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle income, and low-income countries (PURE): a prospective cohort study.
Lancet 2020;395:795–808.